

1103326-0900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Johansson et al.
 Serial No. : 10/560,319
 Filed : December 9, 2005
 For : New Azetidine Compounds
 Examiner : TBA
 Group Art Unit : TBA

Certificate of Mailing Under 37 C.F.R. § 1.8	
I hereby certify that this paper is being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to: Assistant Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450	
Andrew Fessak	48,528
Agent Name	PTO Reg. No.
<i>Andrew Fessak</i>	<i>4/26/06</i>
Signature	Date of Signature

Mail Stop PCT
 Commissioner for Patents
 Box 1450
 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the documents cited on the attached Form PTO/SB/08A is respectfully requested.

The referenced application is the U.S. national stage application of international application no. PCT/SE2004/000901, filed June 9, 2004 (the "PCT application"). The documents identified on the attached Form PTO/SB/08A include documents cited in the specification and/or the International Search Report ("ISR") which issued in connection with the PCT application. Copies of the published PCT application, i.e., International Publication

Number WO 2004/110344, and the ISR were previously submitted on December 9, 2005 with the national stage application transmittal documents.

Copies of Cited U.S. Patent Documents are Not Provided

As announced in the Official Gazette of August 5, 2003, the requirement under 37 CFR 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003 has been waived.

Accordingly, copies of the U.S. patents and/or published patent applications cited on the attached Form PTO/SB/08A are not provided with this Information Disclosure Statement.

Time of Transmittal of Information Disclosure Statement

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3) before the mailing date of the first Office Action on the merits and, therefore, no fee should be due. However, if any fee is required, the Assistant Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: April 26, 2006

Respectfully submitted,

Andrew Fessak

Andrew Fessak
Reg. No. 48,528
Customer No. 007470
White & Case LLP
Direct Dial: (212) 819-8437

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
		Application Number		10/560,319	
		Filing Date		December 9, 2005	
		First Named Inventor		Johansson et al.	
		Art Unit		TBA	
		Examiner Name		TBA	
Sheet		1 of 1		Attorney Docket Number	
				1103326-0900	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
/KH/		US-6,013,652	01-11-2000	Maccoss et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
/KH/		EP-962,457-B1	12-08-1999	Fox et al.		
		EP-791,592-B1	08-27-1997	Mackenzie et al.		
		EP-790-248-B1	08-20-1997	Mackenzie et al.		
		EP-630,887-A1	12-28-1994	Jacobs et al.		
		EP-625,509-B1	11-23-1994	Jacobs et al.		
		EP-625,509-A1	11-23-1994	Jacobs et al.		
		WO-03/37889-A1	05-08-2003	Bialecki et al.		
		WO-02/51807-A1	07-04-2002	Shenvi		
		WO-00/34243	06-15-2000	Ohnmacht		
		WO-00/25766	05-11-2000	Lengel et al.		
		WO-00/20389	04-13-2000	Bernstein et al.		
		WO-00/20003	04-13-2000	Bernstein et al.		
		WO-00/02859	01-20-2000	Bernstein et al.		
		WO-99/01451	01-14-1999	Alker et al.		
		WO-97/27185	07-31-1997	Mackenzie et al.		
		WO-97/25322	07-17-1997	Mackenzie et al.		
		WO-96/24582	08-15-1996	Bernstein et al.		
		WO-96/10568	04-11-1996	Chiang et al.		
		WO-96/05193	02-22-1996	Mackenzie et al.		
		WO-95/15691	06-15-1995	Gamblin et al.		
		WO-95/12577	05-11-1995	Miller		
		WO-95/05377	02-23-1995	Miller		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/KH/		"4-Amino-2-(aryl)-butylbenzamines and their Conformationally Constrained Analogues. Potent Antagonists of the Human Neurokinin-2 (NK ₂) Receptor", Mackenzie et al., Bioorg. Med. Chem. Lett., Volume 13, Number 13, 7 July 2003, pp. 2211-2215(5); available online 15 May 2003.	
Examiner Signature		/Kahsay Habte/	Date Considered
			02/21/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.